922MO Updated ongoing phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors. - Song, Z.; Park, J.; Zhang, Y.; Coward, J.; Voskoboynik, M.; Kichenadasse, G.; Parakh, S.; Powderly, J.; Lin, R.; Lin, X.; Wei, T.; Qu, S.; et al. (Annals of Oncology, 2025)